The reason was presumed that the down-regulation of DcR2 weakened binding activity of NSCLC cells with TRAIL through DcR2; whereas, strengthened their binding activity with TRAIL through DR4 and/or DR5. The gene discussed is TNFRSF10A; the disease is non-small cell lung carcinoma.